TY - BOOK ID - 146315154 TI - Targeting STAT3 and STAT5 in Cancer AU - Gunning, Patrick AU - Keserü, G. M. AU - Moriggl, Richard PY - 2020 PB - Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute DB - UniCat KW - Research & information: general KW - Biology, life sciences KW - multiple myeloma KW - STAT3 KW - S3I-1757 KW - nanoparticle KW - CD38 KW - siRNA/RNAi KW - polyethylenimine KW - PEI KW - lipopolyplex KW - siRNA delivery KW - glioma KW - glioblastoma KW - STAT5 KW - AKT KW - ERK1/2 KW - prolactin KW - androgens KW - prostate cancer KW - knockout KW - escape mechanisms KW - stem/progenitor cells KW - cell hierarchy KW - cancer KW - CD4+ T cells KW - CD8+ T cells KW - myeloid cells KW - immune check point KW - hepatitis C virus (HCV) KW - cirrhosis KW - hepatocellular carcinoma (HCC) KW - endoplasmic reticulum (ER) stress KW - oxidative stress (OS) KW - unfolded protein response (UPR) KW - microRNA-122 (miR-122) KW - nuclear factor erythroid 2-related factor 2 (NRF2) KW - signal transducer and activator of transcription 3 (STAT3) KW - hepatocyte nuclear factor 4 alpha (HNF4A) KW - solid cancers KW - cell cycle KW - apoptosis KW - inflammation KW - mitochondria KW - stemness KW - tumor suppression KW - melanoma KW - autoimmune disease KW - immunotherapy KW - tumor-immune cell interactions KW - breast cancer KW - PD-L1 KW - M2 macrophages KW - NK cells KW - STAT3 inhibitor XIII KW - hedging KW - transaction costs KW - dynamic programming KW - risk management KW - post-decision state variable KW - cancer progression KW - cancer-stem cell KW - cytokine KW - therapy resistance KW - metastasis KW - immunosuppression KW - tumor microenvironment KW - proliferation KW - tyrosine kinase 2 KW - JAK family of protein tyrosine kinases KW - signal transducer and activator of transcription KW - cytokine receptor signaling KW - gain-of-function mutation KW - tumorigenesis KW - ADAM17 KW - interleukin-6 KW - trans-signaling KW - epidermal growth factor receptor (EGF-R) KW - shedding KW - metalloprotease KW - tumor necrosis factor alpha (TNFα) KW - inflammation associated cancer KW - colon cancer KW - lung cancer KW - SH2 domain KW - mutations KW - autosomal-dominant hyper IgE syndrome KW - inflammatory hepatocellular adenomas KW - T-cell large granular lymphocytic leukemia KW - T-cell prolymphocytic leukemia KW - growth hormone insensitivity syndrome KW - nuclear pore complex KW - nuclear transport receptors KW - nucleocytoplasmic shuttling KW - targeting KW - tumor-associated macrophages KW - adoptive T cell therapy KW - immune suppression KW - STAT transcription factors KW - JAK KW - STAT KW - T-PLL KW - T-cell leukemia KW - meta-analysis KW - STAT5B signaling KW - small-molecule inhibitors KW - cancer models KW - companion animals KW - comparative oncology KW - pharmacological inhibitor KW - STAT5 signaling KW - chemotherapy resistance KW - myeloid leukemia KW - heat shock proteins KW - chaperones KW - stabilization KW - targeted therapy KW - ovarian cancer KW - hematopoietic cancers KW - therapeutic targeting KW - pharmacological inhibitors KW - mTOR KW - Bone Marrow Failure Syndromes KW - lymphocytes KW - lymphoma KW - T-cells KW - RHOA KW - NGS KW - MPN KW - JAK2 V617F KW - neoplastic stem cells KW - multiple myeloma KW - STAT3 KW - S3I-1757 KW - nanoparticle KW - CD38 KW - siRNA/RNAi KW - polyethylenimine KW - PEI KW - lipopolyplex KW - siRNA delivery KW - glioma KW - glioblastoma KW - STAT5 KW - AKT KW - ERK1/2 KW - prolactin KW - androgens KW - prostate cancer KW - knockout KW - escape mechanisms KW - stem/progenitor cells KW - cell hierarchy KW - cancer KW - CD4+ T cells KW - CD8+ T cells KW - myeloid cells KW - immune check point KW - hepatitis C virus (HCV) KW - cirrhosis KW - hepatocellular carcinoma (HCC) KW - endoplasmic reticulum (ER) stress KW - oxidative stress (OS) KW - unfolded protein response (UPR) KW - microRNA-122 (miR-122) KW - nuclear factor erythroid 2-related factor 2 (NRF2) KW - signal transducer and activator of transcription 3 (STAT3) KW - hepatocyte nuclear factor 4 alpha (HNF4A) KW - solid cancers KW - cell cycle KW - apoptosis KW - inflammation KW - mitochondria KW - stemness KW - tumor suppression KW - melanoma KW - autoimmune disease KW - immunotherapy KW - tumor-immune cell interactions KW - breast cancer KW - PD-L1 KW - M2 macrophages KW - NK cells KW - STAT3 inhibitor XIII KW - hedging KW - transaction costs KW - dynamic programming KW - risk management KW - post-decision state variable KW - cancer progression KW - cancer-stem cell KW - cytokine KW - therapy resistance KW - metastasis KW - immunosuppression KW - tumor microenvironment KW - proliferation KW - tyrosine kinase 2 KW - JAK family of protein tyrosine kinases KW - signal transducer and activator of transcription KW - cytokine receptor signaling KW - gain-of-function mutation KW - tumorigenesis KW - ADAM17 KW - interleukin-6 KW - trans-signaling KW - epidermal growth factor receptor (EGF-R) KW - shedding KW - metalloprotease KW - tumor necrosis factor alpha (TNFα) KW - inflammation associated cancer KW - colon cancer KW - lung cancer KW - SH2 domain KW - mutations KW - autosomal-dominant hyper IgE syndrome KW - inflammatory hepatocellular adenomas KW - T-cell large granular lymphocytic leukemia KW - T-cell prolymphocytic leukemia KW - growth hormone insensitivity syndrome KW - nuclear pore complex KW - nuclear transport receptors KW - nucleocytoplasmic shuttling KW - targeting KW - tumor-associated macrophages KW - adoptive T cell therapy KW - immune suppression KW - STAT transcription factors KW - JAK KW - STAT KW - T-PLL KW - T-cell leukemia KW - meta-analysis KW - STAT5B signaling KW - small-molecule inhibitors KW - cancer models KW - companion animals KW - comparative oncology KW - pharmacological inhibitor KW - STAT5 signaling KW - chemotherapy resistance KW - myeloid leukemia KW - heat shock proteins KW - chaperones KW - stabilization KW - targeted therapy KW - ovarian cancer KW - hematopoietic cancers KW - therapeutic targeting KW - pharmacological inhibitors KW - mTOR KW - Bone Marrow Failure Syndromes KW - lymphocytes KW - lymphoma KW - T-cells KW - RHOA KW - NGS KW - MPN KW - JAK2 V617F KW - neoplastic stem cells UR - https://www.unicat.be/uniCat?func=search&query=sysid:146315154 AB - Every minute, 34 new patients are diagnosed with cancer globally. Although over the past 50 years treatments have improved and survival rates have increased dramatically for several types of cancers, many remain incurable. Several aggressive types of blood and solid cancers form when mutations occur in a critical cellular signaling pathway, the JAK-STAT pathway; (Janus Kinase-Signal Transducer and Activator of Transcription). Currently, there are no clinically available drugs that target the oncogenic STAT3/5 proteins in particular or their Gain of Function hyperactive mutant products. Here, we summarize targeting approaches on STAT3/5, as the field moves towards clinical applications as well as we illuminate on upstream or downstream JAK-STAT pathway interference with kinase inhibitors, heat shock protein blockers or changing nuclear import/export processes. We cover the design paradigms and medicinal chemistry approaches to illuminate progress and challenges in understanding the pleiotropic role of STAT3 and STAT5 in oncogenesis, the microenvironment, the immune system in particular, all culminating in a complex interplay towards cancer progression. ER -